NCAPG2 and gastric adenocarcinoma: DFI analysis indicated that NCAPG2 serves as a risk agent for 5 cancer types (CESC, KIPAN, KIRP, LIHC, and PAAD) and as a protective factor in STAD and UCS (Fig. 4C).